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CC BY-NC-ND license (http://creativeAbstract Objective: It has been documented that ezrin/radixin/moesin (ERM) phosphoryla-
tion by the p38 mitogen-activated protein kinase (MAPK), Rho/ROCK, and protein kinase C
(PKC) pathways leads to filamentous actin (F-actin) reorganization and microvascular endothe-
lial cell hyperpermeability. In this study, we investigated the effects of Xijiao Dihuang Decoc-
tion combined with Yinqiao Powder (XDY) on influenza virus (IV)-induced F-actin restructuring
and ERM phosphorylation regulated by the Rho/Rho kinase 1 (ROCK), p38 MAPK, and PKC
signaling pathways in pulmonary microvascular endothelial cells (PMVECs).
Methods: Serum containing XDY (XDY-CS; 13.8 g/kg) was acquired using standard protocols for
serum pharmacology. Primary PMVECs were obtained from male Wistar rats and cultured. After
adsorption of IV A (multiplicity of infection, 0.01) for 1 h, medium with 20% XDY-CS was added
to the PMVECs. The distributions of F-actin and phosphorylated ERM were determined by
confocal microscopy, and F-actin expression was measured by flow cytometry. The expression
levels of ROCK1, phosphorylated myosin phosphatase target-subunit (p-MYPT), phosphorylated
MAPK kinase, phosphorylated p38 (p-p38), phosphorylated PKC (p-PKC), and phosphorylated
ERM (p-ERM) were determined by western blotting.
Results: F-actin reorganization in IV-infected PMVECs was reversed by XDY-CS treatment,
which was accompanied by reduced p-ERM production. The p-ERM protein accumulated at
plasma membrane of PMVECs infected with IV, which was also inhibited by XDY-CS treatment.0 64286973; fax: þ86 10 64286871.
il.com (Y. Wu).
f Beijing University of Chinese Medicine.
16.04.002
f Chinese Medicine. Production and hosting by Elsevier B.V. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
Xijiao Dihuang Decoction combined with Yinqiao Powder 51In addition, XDY-CS treatment drastically reduced the levels of p-p38, ROCK1, p-MYPT, and p-
PKC induced by IV infection in PMVECs.
Conclusion: These results show that XDY-CS inhibited influenza-induced F-actin reorganization
in PMVECs by down-regulating p-ERM expression via inhibition of the Rho/ROCK, p38 MAPK, and
PKC pathways. In conclusion, XDY could reduce the damage to endothelial cytoskeleton
induced by IV infection, thus protecting the barriers of PMVECs.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Influenza virus (IV) is a prevalent virus that causes respi-
ratory diseases worldwide. Seasonal viruses spreading
among the human population cause annual epidemics that
lead to approximately 500 000 deaths per year. One of the
major health complications of IV is viral pneumonia, which
can result in acute respiratory distress syndrome (ARDS).1 In
the acute phase of ARDS, symptoms are characterized by
cyanosis, hypoxemia, pulmonary edema, and respiratory
failure, which may ultimately lead to multiple organ failure
and a low survival rate.2
Respiratory failure in the acute phase of ARDS can be
attributed to damage to the epithelial-endothelial barriers
of pulmonary alveoli, where gas exchange takes place.3,4
Damage to these barriers leads to the flooding of protein-
aceous edema fluid containing fibrin, erythrocytes, and
inflammatory cells into the alveolar lumen. Although the
pathogenesis of ARDS is only partially understood, it is
thought that the key determinants of ARDS are endothelial
barrier dysfunction and subsequent pulmonary microvas-
cular endothelial leakage. Clinical analysis showed that
mortality remains high among patients with severe influ-
enza despite the use of anti-viral therapeutic strategies,
which suggests that microvascular leakage may play a
critical role in the pathogenesis of viral infections.5
Xijiao Dihuang Decoction combined with Yinqiao
Powder (XDY) is a classic compound formula originally
prescribed by Jutong Wu, an ancient Chinese physician
from the Qing Dynasty. XDY can clear heat, remove
toxins, cool blood, stop bleeding, and promote blood
circulation.6 Results from a clinical study indicated that
modified Yinqiao Powder could ameliorate symptoms and
shorten the duration of fever caused by H1N1 IV.7 Xijiao
Dihuang Decoction, currently referred to as Qingre
Dihuang Decoction, has been evaluated as a treatment
for blood-heat syndrome in modern studies. Xijiao
Dihuang Decoction was beneficial in treating syndromes
where toxins intrude into the blood, a phenomenon that
occurs in severe acute respiratory syndrome (SARS).8 For
example, modified Xijiao Dihuang Decoction was used to
treat fire-toxin syndrome caused by viral pneumonia by
virtue of its abilities for clearing heat, cooling blood,
nourishing yin, and dispelling phlegm.9 In previous
studies, we showed that XDY treatment clearly reduced
the mortality rate, decreased pulmonary permeability,
and alleviated pulmonary edema in mice with viral
pneumonia.10 The results from in vitro studiesdemonstrated that XDY could protect the endothelial
barrier by reversing permeability increases in PMVECs
caused by IV infection.11 However, the mechanisms by
which XDY mitigates hyper-permeability in IV-infected
PMVECs requires further investigation.
The Ezrin/Radixin/Moesin (ERM) protein forms links be-
tween the cytomembrane and the cytoskeleton. The
integrity of the cytoskeleton is mediated by ERM phos-
phorylation and is crucial for the maintenance of both
endothelial morphology and permeability. It has been well
documented that ERM can be phosphorylated via the p38
mitogen-activated protein kinase (MAPK), Rho/Rho kinase
(ROCK), and protein kinase C (PKC) pathways, thus leading
to rearrangement of filamentous actin (F-actin) and hyper-
permeability of microvascular endothelial cells.12e14
Therefore, in this study, we focused on the effects of
XDY on F-actin rearrangement in IV-infected PMVECs.
Furthermore, we explored the underlying mechanisms by
determining its effects on ERM phosphorylation, as well as
its roles in activating the Rho/ROCK, p38 MAPK, and PKC
pathways, which serve as upstream activators of the ERM
protein.Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium, Medium 199 (M199),
and fetal bovine serum (FBS) were purchased from Thermo
Fisher Scientific (Waltham, MA, USA). Endothelial cell
growth supplement (ECGS) was purchased from Becton,
Dickinson and Company (Bergen, NJ, USA). Fluorescein
isothiocyanate labeled-phalloidin (phalloidin-FITC) was
purchased from SigmaeAldrich (St Louis, MO, USA). The
reagent 40,6-diamidino-2-phenylindole (DAPI) was pur-
chased from Boster (Wuhan, Hubei, China). Bovine serum
albumin (BSA) was obtained from Amresco (Solon, OH,
USA). Paraformaldehyde and Triton-X-100 were purchased
from Beijing Bioway Biotech Group (Beijing, China). Anti-
bodies against phosphorylated ERM (p-ERM) and phosphor-
ylated PKC (p-PKC) were obtained from Cell Signaling
Technology (Danvers, MA, USA). Antibodies against phos-
phorylated MAPK kinase (p-MKK), phosphorylated p38 (p-
p38), and ROCK1 were purchased from Abcam (Cambridge,
England, UK). An antibody against phosphorylated myosin
phosphatase target-subunit (p-MYPT) was purchased from
Abnova (Taipei, Taiwan, China). Recombinant
52 Z. Xuan et al.glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
obtained from Proteintech (Chicago, IL, USA). A
DyLight594-conjugated goat anti-rabbit secondary antibody
was purchased from Beijing ComWin Biotech (Beijing,
China). b-actin was obtained from Santa Cruz Biotech-
nology (Dallas, Texas, USA). The Enhanced Chem-
iluminescence (ECL) Western Blot Detection System and
polyvinylidene fluoride (PVDF) membranes were obtained
from Millipore (Bedford, MA, USA). MadineDarby canine
kidney (MDCK) cells were obtained from the Chinese
Academy of Medical Sciences (Shanghai, China).Preparation of XDY
Thirty grams of rhinoceros horn (Rhinoceros nicornis
LR.simus Burchell ) (replaced with bubali cornu now), 30 g
of rehmanniae radix (Rehmannia glutinosa (Gaetn.)
Libosch.), 12 g of paeoniae radix rubra (Paeonia lactiflora
Pall.), 9 g of moutan cortex (Paeonia suffruticosa Andr.),
9 g of forsythiae fructus (Forsythia suspensa (Thunb.)
Vahl ), 9 g of lonicerae japonicae flos (Lonicera japonica
Thunb.), 6 g of platycodonis radix (Platycodon grandiflorum
(Jacq.) A.DC.), 6 g of menthae herba (Mentha haplocalyx
Briq.), 4 g of lophatheri herba (Lophatherum gracile
Brongn.), 5 g of glycyrrhizae radix (Glycyrrhiza uralensis
Fisch.), 5 g of schizonepetae herba (Schizonepeta ten-
uifolia Briq.), 5 g of sojae semen praeparatum (Glycine
max (L.) Merr.), and 9 g of arctii fructus (Arctium lappa L.)
were purchased from Dongzhimen Hospital, Beijing Uni-
versity of Chinese Medicine. These materials were soaked
in distilled water for 1 hour then boiled the first time in
water (w/v, 1/10) for 1 hour and 15 min, and then boiled
the second time in water (w/v, 1/6) for 15 minutes. The
resulting solution was concentrated to a final density of
2.07 g/mL.Preparation of XDY-containing serum (XDY-CS)
The study was performed according the “Principles of
Laboratory Animal Care” guidelines published by the
World Health Organization.15 And experiments were
approved by the Institutional Animal Ethics Committee of
Beijing University of Chinese Medicine. Male Wistar rats
weighing 270e310 g were obtained from Vital River Lab-
oratories (Beijing, China) and randomly divided into 2
groups: (1) XDY-CS group: 10 rats were administered XDY
solution by intragastric gavage in twice-daily doses of
13.8 g/kg (4 mL/rat) for 3 days. This dose was equal to 6
times that used previously with adult-dosage. (2) Control
serum (Con-S) group: 10 rats were administered saline
using the same treatment schedule and volumes described
for the XDY-CS group. At 1 hour after the last adminis-
tration, blood was obtained from abdominal the aorta and
stored at 25  1C for 4 h. Serum was isolated by centri-
fugation (3000 rpm, 15 minutes), inactivated at 56C for
30 min, and stored at 70C in preparation for further
experiments.IV propagation
Mouse-adapted IV strain A/FM/1/47 was purchased from
the Institute of Virus Research in the Chinese Center for
Disease Control and Prevention, and was propagated in 9-
day-old embryonated eggs (Beijing Merial Vital Laboratory
Animal Technology (Beijing, China).). The 50% tissue
culture-infectious dose (TCID50) was determined by per-
forming a cytopathic effect (CPE) assay, according to the
method of Reed and Muench. The TCID50 of IV strain A/FM/
1/47 was 104.6/mL. PMVECs were infected with IV at a
multiplicity of infection (MOI) of 0.01.
Rat PMVEC culture
Four-week-old, male Wistar rats weighing 70e90 g were
obtained from Vital River Laboratories (Beijing, China).
PMVECs were isolated and cultured according to previous
methods,16,17 with some modifications. Briefly, 1-mm-
thick tissue samples were removed from periphery of
fresh lungs separated from rats and cut into 1-mm3 pieces.
Next, 25 of the 1-mm3 lung pieces were placed in 1%
gelatin-coated T25 cell flasks. The flasks were inverted
and placed in an incubator (37C, 5% CO2) for 2 h, after
which the flasks were stood upright and 1 mL of medium
was added to each flask. The medium comprised M199
supplemented with 20% FBS, ECGS (100 mg/mL), and 1%
penicillin-streptomycin solution. After a 60-h incubation,
the tissues were abandoned, and 5 mL medium was added
to individual T25 flasks. At approximately 90% confluence,
the PMVECs were detached using 0.25% trypsin/0.02%
EDTA and subcultured into new T25 flasks. PMVECs were
identified according to morphological and functional
criteria, and confluent PMVECs from the first 3 passages
were used for experiments conducted with 3 groups. Cells
in the control group were incubated with M199 containing
20% Con-S. Cells in the virus group were infected with IV A
(MOI, 0.01) for 1 hour, and then incubated with M199
containing 20% Con-S. Cells in the XDY group were infec-
ted with IV A (MOI, 0.01) for 1 hour, and then incubated
with M199 containing 20% XDY-CS. After the cells in each
group were incubated for 24 h, they were used for the
experiments described in Sections 2.6e2.8.
Flow cytometry
After washing PMVECs growing in 6-well plates twice with
phosphate buffered saline (PBS), they were collected and
fixed in 4% paraformaldehyde at 4C. After permeabiliza-
tion with 0.25% Triton-100, the cells were labeled for 40
minutes with 1 mg/mL phalloidin-FITC. Samples were then
evaluated using a FACSCanto flow cytometer (Becton
Dickinson, San Jose, CA), and the data were analyzed using
BD FACS Diva software.
Confocal microscopy
PMVECs grown in 8-well RS glass side (Nunc, Denmark) were
washed with PBS, fixed using 4% paraformaldehyde at 4C,
permeabilized using 0.5% Triton X-100, and blocked using
5% BSA. PMVECs were then incubated with an anti-p-ERM
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secondary antibody (1:800). F-actin was labeled using
phalloidin-FITC (1 mg/mL) after the cells were pre-
incubated with BSA. The images were collected with an
FV1000 confocal microscope (Olympus, Japan).Western blotting
After XDY-CS administration, cells were collected with a
cell scraper and lysed in RIPA buffer. The lysate was
centrifuged at 4C (12,000 rpm, 30 min), and the total
amount of protein contained in the supernatant was
detected by using a BCA kit (Applygen, Beijing, China).
Equivalent total protein samples were separated by 5%
sodium dodecyl sulfate polyacrylamide gel electrophoresis
and electro-transferred onto a PVDF membrane. The
membranes were blocked with 5% nonfat milk for 1 hour at
27C and then incubated with a corresponding primary
antibody at 4C overnight. After incubation with a sec-
ondary antibody at 27C for 1 hour on the following day,
immune-reactive bands were detected using the ECL Plus
Western Blotting Detection Kit (Wuhan Boster Biotech
Group, Hubei, China). The levels of p-ERM, p-p38, p-MKK,
ROCK1, p-MYPT, and p-PKC were examined using corre-
sponding primary antibodies diluted 1:1000, 1:2000,Fig. 1 Effect of XDY-CS on IV-induced F-actin reorganization (6
grown in medium containing XDY-CS for 24 h, F-actin in the cytosk
microscopy. Three independent experiments were performed in tr1:800, 1:3000, 1:20, and 1:1000 in 5% nonfat milk,
respectively.
Statistical analysis
Results are reported as the mean (SEM). Data were analyzed
by student’s t test for data between 2 groups using Prism
software, version 5.0c (GraphPad Software, USA). The dif-
ferences were considered significant when P < .05.
Results
Effect of XDY-CS on IV-induced F-actin
reorganization
PMVECs in the control group showed a normal, spindle-
shaped morphology. In the control group, a continuous F-
actin distribution was observed mainly in the cortical areas
of cells without stress fibers. In the virus group, F-actin in
PMVECs reorganized, showing thickening and bundling in
the cytoplasm, with the formation of thick stress fibers.
Growth in the presence of XDY-CS reversed the F-actin
rearrangement observed in IV-infected PMVECs. Cyto-
plasmic F-actin accumulation and stress fiber formation
induced by IV infection were also alleviated by XDY-CS
treatment (Fig. 1).0). Scale bars: 10 mm. After PMVECs were infected with IV and
eleton (green) and nuclei (blue) were examined using confocal
iplicate.
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regulation
In the virus group, F-actin expression in PMVECs increased
remarkably, compared with that observed in the normal
group (P< .05). IV-dependent F-actin induction was reduced
in the XDY group; however, the difference between the virus
group and the XDY group was not significant (P> .05; Fig. 2).Effect of XDY-CS on the p-ERM level in IV-infected
PMVECs
In the virus group, the p-ERM level significantly increased,
compared with that observed in the control group (P < .01).
The difference in p-ERM levels between the virus and XDY-
CS groups was statistically significant, which implied that
XDY-CS inhibited IV-induced ERM phosphorylation in PMVECs
(P < .05; Fig. 3).Fig. 2 Effect of XDY-CS on IV-induced F-actin up-regulation. (A
determined by flow cytometry. (B) MFI levels. After PMVECS were tr
flow cytometry. F-actin MFIs were calculated using Image software.
Data are expressed as the mean (SEM). *: P < .05.Effect of XDY-CS on p-ERM distribution in IV-
infected PMVECs
Weak fluorescent detection of p-ERM in PMVECs was
observed with the control group. p-ERM relocated to the
border and showed enhanced detection in IV-infected
PMVECs, as compared with that observed with the control
group. XDY-CS treatment inhibited IV-induced p-ERM
expression and redistribution to the periphery of PMVECs
(Fig. 4).Effect of XDY-CS on p-MKK and p-p38 production in
IV-infected PMVECs
IV infection promoted significantly higher p-p38 and p-MKK
production in PMVECs (P < .001), compared with that
observed in the control group (Fig. 5). The p-p38 level was
approximately 3-fold higher in the virus group relative to
the control group, and p-MKK production was) Effect of XDY-CS on virus-induced F-actin up-regulation, as
eated as indicated for 24 h, F-actin expression was measured by
Three independent experiments were performed in triplicate.
Fig. 3 Effect of XDY-CS on p-ERM production in IV-infected
PMVECs. (A) Western blot analysis of p-ERM production in
PMVECs. GADPH was detected as an internal reference. (B)
Quantitative evaluation of p-ERM bands by densitometry.
PMVECs were harvested 24 h after the indicated treatments
and analyzed by western blotting using an anti-p-ERM antibody.
Three independent experiments were performed in triplicate.
Data are expressed as the mean (SEM). *: P < .05; **: P < .01.
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cantly attenuated IV-induced p38 phosphorylation
(P < .05). Although p-MKK production in the XDY group was
lower than that in the virus group, the difference was not
statistically significant (P > .05). These data suggested that
XDY might inhibit IV-induced activation of the p38 MAPK
pathway.
Effect of XDY-CS on ROCK1 and p-MYPT levels in IV-
infected PMVECs
To determine whether ERM is phosphorylated by the Rho/
ROCK pathway and whether such phosphorylation can be
inhibited by XDY-CS, we first assessed ROCK1 expression by
western blotting. The production of p-MYPT was also stud-
ied because MYPT is a main substrate of ROCK that regu-
lates myosin light chain phosphatase (MLC)
phosphorylation. IV infection significantly increased ROCK1
and p-MYPT levels (P < .001) compared with those in the
control group. Treatment with XDY-CS significantly down-
regulated virus-induced ROCK1 and p-MYPT overexpression
in PMVECs (P < .001, P < .001; Fig. 6).
Effect of XDY-CS on p-PKC production in IV-infected
PMVECs
The production of p-PKC was significantly increased by IV
infection (P < .05), compared with that in the controlgroup. As expected, XDY-CS treatment significantly
reduced p-PKC levels in IV-infected PMVECs (P < .05).
These data indicated that XDY-CS might ameliorate virus-
induced endothelial dysfunction by modulating the PKC
pathway (Fig. 7).Discussion
Disruption of the pulmonary microvascular endothelial
barrier can lead to the movement of fluid into the pulmo-
nary air spaces, ultimately resulting in ARDS, acute lung
injury, or pulmonary edema.18,19 Microfilaments (such as
actin filaments) are closely linked with vascular endothelial
permeability. F-actin rearrangement leads to stress fiber
formation, the stretching of which in turn contributes to
paracellular gap formation and eventually to permeability
increases.20
ERM-family proteins are crucial in regulating cell struc-
tures and functions. They serve as linkers between the
plasma membrane and the actin cytoskeleton via N-termi-
nal binding to membrane-adhesion molecules and C-ter-
minal binding to actin. A conserved threonine residue is
found in their respective C-terminal regions, namely T567
in ezrin, T564 in radixin, and T558 in moesin. An important
mechanism of ERM-family regulation occurs through phos-
phorylation of their respective conserved threonine resi-
dues.21 Phosphorylation of the conserved threonine residue
causes conformational changes in ERM, which unmasks
binding sites for effector proteins.22 Rho kinase, p38 MAPK,
and PKC are 3 kinases that are thought to phosphorylate
ERM proteins. Previous studies have also provided evidence
that these kinases modulate endothelial cell
permeability.21,22
Various stimuli can promote ERM phosphorylation in
endothelial cells. The p-ERM protein mainly localizes to the
border of PMVECs, where it can link cytoskeletal and
membrane elements, leading to the formation of stress fi-
bers and paracellular gaps, eventually contributing to
permeability increases. Previously, it was reported that
ERM phosphorylation induced by TNF-a may trigger
permeability increases in human PMVECs via the p38 MAPK
and PKC pathways.20 Previous findings also showed that
thrombin23 and 2-methoxyestradiol24 can mediate endo-
thelial permeability increases by ERM phosphorylation via
the PKC pathway. ERM protein phosphorylation via the p38
MAPK and Rho/ROCK pathways can also participate in
modulating endothelial permeability induced by advanced
glycation end products.25 Previously, we showed that IV
infection increased microvascular leakage in PMVECs, with
the primary mechanism being related to activation of the
Rho/ROCK, p38 MAPK, and PKC pathways, ultimately lead-
ing to ERM phosphorylation.11
XDY is a classic traditional medicine that is used for
treating viral pneumonia induced by IV infection. Previ-
ously, we showed that XDY administration reduced mor-
tality rates in mice with viral pneumonia.10 Results from
this prior study demonstrated that XDY reduced virus-
induced permeability increases, as well as pulmonary
inflammation and vascular injuries induced by IV. In addi-
tion, it was confirmed that a dosage of 13.8 g/kg (equiva-
lent to the clinical dosage) was the most effective.
Fig. 4 Effect of XDY-CS on p-ERM distribution in IV-infected PMVECs (60).Scale bars, 10 mm. After PMVECs were treated as
indicated for 24 h, the distribution of p-ERM (red) and nuclei (blue) were examined by confocal microscopy. Representative data
from 3 independent experiments are shown. Three replicates were performed in each experiment.
Fig. 5 Effect of XDY-CS on p-MKK and p-p38 levels in IV-infected PMVECs. (A) The production of p-p38 and p-MKK was analyzed by
western blotting. GADPH was detected as an internal reference. (B) Quantitative evaluation of p-MKK and p-p38 bands by
densitometry. Three independent experiments were performed in three replicates. The data shown are expressed as the mean
(SEM). *: P < .05; ***: P < .001.
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Fig. 6 Effect of XDY-CS on ROCK1 and p-MYPT production in IV-infected PMVECs. (A) ROCK1 and p-MYPT levels were analyzed by
western blotting. GADPH was detected as an internal reference. (B) Quantitative evaluation of ROCK1 and p-MYPT bands by
densitometry. Three independent experiments were performed in three replicates. Data are expressed as the mean (SEM). ***:
P < .001.
Xijiao Dihuang Decoction combined with Yinqiao Powder 57Therefore, to gain insight into the mechanism whereby XDY
protects the vascular endothelium, we studied the effects
of XDY-SC in mice at a clinical-dose equivalent on F-actin
and ERM-related pathways in IV-infected PMVECs.Fig. 7 Effect of XDY-CS on p-PKC production in IV-infected
PMVECs. (A) The production of p-PKC was analyzed by west-
ern blotting. b-actin was detected as an internal reference. (B)
Quantitative evaluation of p-PKC bands by densitometry. Three
independent experiments were performed in three replicates.
Data are expressed as the mean (SEM). *: P < .05.In the study, XDY-CS dramatically reduced IV-induced
stress fiber formation and F-actin accumulation in the
cytoplasm. However, the difference of F-actin expression
between virus group and XDY group was not statistically
significant, suggesting that XDY-CS mainly alleviated F-actin
rearrangement rather than reducing its expression.
We also determined the effect of XDY-CS on phosphor-
ylation of the ROCK substrate MYPT. Previous data
demonstrated that ROCK is upregulated in endothelial cells
infected with virus.26 The activation of ROCK promotes
MYPT phosphorylation, thus activating MLC and promoting
actin-filament polymerization. That MYPT expression was
reduced in XDY-CS-treated PMVECs indicated that IV-
induced F-actin reorganization was reversed by XDY-CS via
the inhibition of MLC phosphorylation. The integrity of
endothelial cell cytoskeletons, which are mediated by MLC
phosphorylation, is indispensable for endothelial cell
functions. MYPT phosphorylation can promote ERM phos-
phorylation, suggesting that common pathways may be
shared between MLC and ERM.27 Therefore, the effect of
XDY-CS on F-actin reorganization might be linked with MLC
regulation, a possibility that we intend to study in the
future.
Interestingly, the cytoskeletal changes observed were
not solely linked with the hyperpermeability of PMVECs, but
were also related to virus replication. Actin polymerization
is augmented in IV-infected cells, which is accompanied by
activation of the Raf/MEK/ERK and PKC pathways, as well
as calcium and phospholipase C production.28e30 F-actin
rearrangement can facilitate viral transportation into the
nucleus via gene regulation or activation of the F-actin
transportation system in the cytoplasm.26 Although we did
not observe that XDY inhibited viral replication in IV-
infected PMVECs (data not shown), which might have
58 Z. Xuan et al.been due to the interference of serum with virus replica-
tion in vitro, we did detect the reduction of viral titers in
lung tissue of IV-infected mice. Because F-actin rear-
rangement is involved in IV replication, the ability of XDY to
inhibit IV replication in vivo might be due to its capacity to
reverse IV-induced F-actin reorganization. However,
whether XDY inhibits IV replication by interfering with ERM
phosphorylation remains unclear, since the role of ERM
phosphorylation in IV replication remains uncertain, which
merits further investigation.
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